CALLE DOCTOR FLEMING, 51 | 28036 MADRID, SPAIN
+34 91 3459395 | +44 (0) 20 3951 8071
info@oxonepi.com

New Study Published in JAMA Cardiology: ICDs vs. Amiodarone in Chagas Cardiomyopathy

JAMA Cardiology

Evaluating ICDs’ Role in Reducing Sudden Cardiac Death Among High-Risk Patients

OXON Epidemiology’s latest study, recently featured in JAMA Cardiology, provides critical insights into the effectiveness of implantable cardioverter-defibrillators (ICDs) compared to amiodarone in reducing sudden cardiac death among patients with chronic Chagas cardiomyopathy. Known as the CHAGASICS Randomized Clinical Trial, the study enrolled 323 patients in Brazil who were at moderate to high risk for sudden cardiac death, focusing on whether ICDs could reduce overall mortality rates more effectively than amiodarone.

The findings reveal no major difference in overall death rates between the two groups; however, ICDs were notably more effective in preventing sudden cardiac death and reducing hospitalizations for heart-related issues. This outcome suggests that ICDs may play a valuable role in managing critical heart risks within this specific patient population, providing new insights for healthcare providers in cardiology.

As an organization committed to improving patient care through evidence-based research, OXON Epidemiology regularly combines the rigor of randomized clinical trials (RCTs) with the insights from real-world evidence (RWE) studies to guide healthcare practices. This study underscores the importance of RCTs in understanding treatment efficacy, while RWE plays a complementary role by illustrating how treatments perform in everyday clinical settings. Together, RCTs and RWE provide a comprehensive understanding of treatment effectiveness, supporting data-driven decisions in cardiology.

Explore about our expertise in RWE and RCTs

Discover how OXON can support your research and development initiatives.
We invite you to contact us to explore new opportunities and drive forward the progress in Cardiology research.